Abraxane as adjuvant misses primary in resected pancreatic cancer

Celgene said Abraxane nab-paclitaxel plus gemcitabine missed the primary

Read the full 90 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE